Elbasvir/grazoprevir (Zepatier™) is a hepatitis C virus (HCV) medication used to treat chronic hepatitis C. The medication works by inhibiting viral replication. Elbasvir and grazoprevir are substrates of CYP3A4 and P-glycoprotein (P-gp). Coadministration with moderate or strong CYP3A4 inhibitors or inducers is likely to result in interactions. Grazoprevir is a substrate of OATP1B1/3 transporters. Coadministration with medications that inhibit OATP1B1/3 should be avoided.
This three-page quick guide for clinicians summarizes the mechanism of action, route of metabolism, and drug interaction potential of elbasvir/grazoprevir (Zepatier™) for hepatitis C treatment. It lists recommendations for concurrent use with HIV protease inhibitors, non-nucleoside reverse transcriptase inhibitors, integrase strand transfer inhibitors, entry inhibitors, and nucleoside/nucleotide reverse transcriptase inhibitors.
The guide also covers common primary care medications, including antibiotics, anticonvulsants, antifungals, antimycobacterials, endothelin antagonists, herbal products, HMG-CoA reductase inhibitors, immunosuppressants, and wakefulness-promoting agents, with dosing limits and monitoring notes where stated.
| Medication class | NS5a inhibitor and NS3/4A protease inhibitor |
|---|---|
| CYP3A4 and P-gp status | Elbasvir and grazoprevir are substrates of CYP3A4 and P-glycoprotein (P-gp) |
| OATP1B1/3 status | Grazoprevir is a substrate of OATP1B1/3 transporters |
| Atorvastatin maximum dose with concurrent use | 20 mg daily |
| Rosuvastatin maximum dose with concurrent use | 10 mg daily |
Elbasvir/grazoprevir is an NS5a inhibitor and NS3/4A protease inhibitor used for HCV.
No. Co-administration is not recommended because of potential hepatotoxicity and increased grazoprevir plasma concentrations.
Elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine (Stribild®) and elvitegravir/cobicistat/tenofovir alafenamide/emtricitabine (Genvoya®) are not recommended because cobicistat is likely to increase elbasvir and grazoprevir concentrations.
Do not exceed atorvastatin 20 mg daily or rosuvastatin 10 mg daily. For fluvastatin, lovastatin, and simvastatin, use the lowest doses and titrate with close monitoring.